These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45 related articles for article (PubMed ID: 9454727)
1. Effect of changes in the glycosylation of the human immunodeficiency virus type 1 envelope on the immunoreactivity and sensitivity to thrombin of its third variable domain. Papandreou MJ; Fenouillet E Virology; 1998 Feb; 241(1):163-7. PubMed ID: 9454727 [TBL] [Abstract][Full Text] [Related]
2. Recombinant HIV envelope expressed in an alpha-glucosidase I-deficient CHO cell line and its parental cell line in the presence of 1-deoxynojirimycin is functional. Fenouillet E; Papandréou MJ; Jones IM Virology; 1997 Apr; 231(1):89-95. PubMed ID: 9143306 [TBL] [Abstract][Full Text] [Related]
3. Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines. Fenouillet E; Miquelis R; Drillien R Virology; 1996 Apr; 218(1):224-31. PubMed ID: 8615025 [TBL] [Abstract][Full Text] [Related]
4. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Kang CY; Luo L; Wainberg MA; Li Y Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338 [TBL] [Abstract][Full Text] [Related]
5. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies. Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663 [TBL] [Abstract][Full Text] [Related]
6. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298 [TBL] [Abstract][Full Text] [Related]
7. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein. Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203 [TBL] [Abstract][Full Text] [Related]
8. The alpha-glucosidase inhibitor 1-deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step. Papandréou MJ; Barbouche R; Guieu R; Kieny MP; Fenouillet E Mol Pharmacol; 2002 Jan; 61(1):186-93. PubMed ID: 11752220 [TBL] [Abstract][Full Text] [Related]
9. Effect of a glucosidase inhibitor on the bioactivity and immunoreactivity of human immunodeficiency virus type 1 envelope glycoprotein. Fenouillet E; Gluckman JC J Gen Virol; 1991 Aug; 72 ( Pt 8)():1919-26. PubMed ID: 1678778 [TBL] [Abstract][Full Text] [Related]
10. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. Hu Q; Trent JO; Tomaras GD; Wang Z; Murray JL; Conolly SM; Navenot JM; Barry AP; Greenberg ML; Peiper SC J Mol Biol; 2000 Sep; 302(2):359-75. PubMed ID: 10970739 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of V3-specific cleavage of recombinant HIV-1 gp120 produced in Chinese hamster ovary cells. Du SX; Xu L; Viswanathan S; Whalen RG Protein Expr Purif; 2008 Jun; 59(2):223-31. PubMed ID: 18406166 [TBL] [Abstract][Full Text] [Related]
12. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step. Barbouche R; Decroly E; Kieny MP; Fenouillet E Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419 [TBL] [Abstract][Full Text] [Related]
13. Functional complementation of the envelope hypervariable V3 loop of human immunodeficiency virus type 1 subtype B by the subtype E V3 loop. Sato H; Kato K; Takebe Y Virology; 1999 May; 257(2):491-501. PubMed ID: 10329559 [TBL] [Abstract][Full Text] [Related]
14. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1. Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967 [TBL] [Abstract][Full Text] [Related]
15. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. Labrosse B; Treboute C; Brelot A; Alizon M J Virol; 2001 Jun; 75(12):5457-64. PubMed ID: 11356952 [TBL] [Abstract][Full Text] [Related]
16. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. Ogert RA; Lee MK; Ross W; Buckler-White A; Martin MA; Cho MW J Virol; 2001 Jul; 75(13):5998-6006. PubMed ID: 11390601 [TBL] [Abstract][Full Text] [Related]
17. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Kang SM; Quan FS; Huang C; Guo L; Ye L; Yang C; Compans RW Virology; 2005 Jan; 331(1):20-32. PubMed ID: 15582650 [TBL] [Abstract][Full Text] [Related]
18. The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Herrera C; Klasse PJ; Michael E; Kake S; Barnes K; Kibler CW; Campbell-Gardener L; Si Z; Sodroski J; Moore JP; Beddows S Virology; 2005 Jul; 338(1):154-72. PubMed ID: 15932765 [TBL] [Abstract][Full Text] [Related]
19. Expression, purification, and isotope labeling of a gp120 V3 peptide and production of a Fab from a HIV-1 neutralizing antibody for NMR studies. Sharon M; Görlach M; Levy R; Hayek Y; Anglister J Protein Expr Purif; 2002 Apr; 24(3):374-83. PubMed ID: 11922753 [TBL] [Abstract][Full Text] [Related]
20. [Evaluation of diagnostic efficiency of the recombinant protein modeling immunodominant epitope V3 of envelope gp120 for immunoenzyme detection for HIV-1 infection antibodies]. Riabinina SA; Baranova EN; Sharipova IN; Susekina MI; Puzyrev VF; Obriadina AP; Burkov AN; Ulanova TI Mol Gen Mikrobiol Virusol; 2007; (3):33-6. PubMed ID: 17886471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]